A detailed history of Comerica Bank transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Comerica Bank holds 1,809 shares of APLS stock, worth $59,950. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,809
Previous 8,355 78.35%
Holding current value
$59,950
Previous $320,000 83.75%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$28.84 - $41.15 $188,786 - $269,367
-6,546 Reduced 78.35%
1,809 $52,000
Q2 2024

Aug 15, 2024

BUY
$38.07 - $59.71 $7,309 - $11,464
192 Added 2.35%
8,355 $320,000
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $376,873 - $493,085
6,804 Added 500.66%
8,163 $479,000
Q4 2023

Feb 14, 2024

SELL
$37.14 - $64.82 $3.52 Million - $6.15 Million
-94,820 Reduced 98.59%
1,359 $81,000
Q3 2023

Nov 21, 2023

BUY
$23.65 - $89.22 $2.27 Million - $8.58 Million
96,179 New
96,179 $3.66 Million
Q4 2022

Jan 26, 2023

BUY
$43.24 - $61.04 $2.86 Million - $4.04 Million
66,230 New
66,230 $0

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.